5:29 PM
 | 
Dec 13, 2013
 |  BC Extra  |  Clinical News

AbbVie's veliparib graduates I-SPY 2

Researchers at the University of California, San Francisco and colleagues said a regimen containing veliparib ( ABT-888) from AbbVie Inc. (NYSE:ABBV) "graduated" from the open-label Phase II I-SPY 2 trial based on having a high probability of success in patients with triple-negative breast cancer (TNBC) in a Phase III trial. I-SPY 2 is designed...

Read the full 259 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >